Moderna (MRNA) raises lower end of its 2021 global COVID-19 vaccine manufacturing plan to 600 million doses

Market news

4 January 2021

Moderna (MRNA) raises lower end of its 2021 global COVID-19 vaccine manufacturing plan to 600 million doses

Moderna increased its base-case global production estimate for its COVID-19 vaccine from 500 million to 600 million doses for 2021. It said that it is continuing to invest and add staff to build up to potentially 1 billion doses for 2021.

The company also said it expects about 100 million doses to be available in the U.S. by the end of Q1 2021, with 200 million doses total available by the end of Q2.

U.S.: Manufacturing PMI, December 57.1 (forecast 56.5)

U.S. Stocks open: Dow -0.06%, Nasdaq +0.29%, S&P +0.14%

Market Focus

Material posted here is solely for information purposes and reliance on this may lead to losses. Past performances are not a reliable indicator of future results. Please read our full disclaimer

Open Demo Account & Personal Page

Personal area

support@teletradepartners.com

Risk Warning: Trading in the financial markets (including trading on margin) provides a wide range of opportunities and enables investors ready to take risks to make high profits, but it carries a potentially high level of risk of loss. Therefore, prior to trading you should take into careful consideration whether such operations are suitable for you in terms of your level of knowledge and financial situation.